Media advisory: Experts from Glenn Biggs Institute at UT Health San Antonio available to discuss new Alzheimer’s drug
June 9, 2021
The U.S. Food and Drug Administration (FDA) on Monday, June 7, approved the drug aducanumab for the treatment of Alzheimer’s disease, which affects 6.2 million Americans. Sudha Seshadri, MD, professor of neurology at UT Health San Antonio and director of the university’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, issued the following statement: “We are excited that a drug, aducanumab (Aduhelm, from Biogen), has been approved by the FDA for treatment of persons with early symptoms due to Alzheimer’s disease. This is the first new drug approved for Alzheimer’s in two decades.”
